Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for MDXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 -13.27M
March 31, 2026 -2.585M
December 31, 2025 -0.583M
September 30, 2025 -0.857M
June 30, 2025 -1.094M
March 31, 2025 -2.878M
December 31, 2024 -1.501M
September 30, 2024 0.027M
June 30, 2024 -0.359M
March 31, 2024 -32.37M
December 31, 2023 -8.94M
September 30, 2023 0.37M
June 30, 2023 0.004M
March 31, 2023 -0.004M
December 31, 2022 0.066M
September 30, 2022 0.13M
June 30, 2022 0.26M
March 31, 2022 -1.036M
December 31, 2021 0.022M
September 30, 2021 -0.15M
June 30, 2021 -0.916M
March 31, 2021 -2.308M
December 31, 2020 -1.243M
September 30, 2020 66.73M
June 30, 2020 -1.753M
Date Value
March 31, 2020 -2.177M
December 31, 2019 -1.138M
September 30, 2019 -1.707M
June 30, 2019 66.75M
March 31, 2019 -1.044M
December 31, 2018 -0.285M
September 30, 2018 -0.224M
June 30, 2018 -0.334M
March 31, 2018 -8.091M
December 31, 2017 -24.59M
September 30, 2017 -27.57M
June 30, 2017 4.905M
March 31, 2017 -13.14M
December 31, 2016 0.592M
September 30, 2016 -6.531M
June 30, 2016 0.894M
March 31, 2016 -3.106M
December 31, 2015 -18.54M
September 30, 2015 -3.731M
June 30, 2015 -2.911M
March 31, 2015 -11.05M
December 31, 2014 0.8889M
September 30, 2014 -0.0683M
June 30, 2014 -4.153M
March 31, 2014 1.186M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. -0.701M
Perspective Therapeutics, Inc. 0.147M
ABVC BioPharma, Inc. 0.2262M
Enovis Corp. -50.56M
Edwards Lifesciences Corp. -0.30M